Two landmark events occurred for CAR-T cell therapy in 2017: two anti-CD19 CAR-T cells were approved by FDA for the therapy of acute lymphoblastic leukemia (ALL) and relapsed or refractory large B-cell lymphoma, respectively. From then, increasing number of researchers have been dedicated to CAR-T cell therapy research.
What is CAR-T cell therapy？It is a kind of cell immunotherapy featured by its distinct research procedures (depicted in Fig. 1): Peripheral blood is collected from the patient firstly. Then T cells are isolated and stimulated. The cells are cultured and expanded after genetically engineered to express chimeric antigen receptors (CARs), which can recognize a specific tumor associated antigen, such as CD19, BCMA and CD20. Finally, the CAR-T cells will go through quality control and are reinfused into the patient.
Sino Biological Inc. provides not only quality CAR-T cell therapy target proteins, but also varied research reagents for the whole process of CAR-T cell therapy, such as high-quality cytokines, T cell related FACS antibodies, T cell activation antibodies, cytokine ELISA kits, apoptosis detection kits, Sinofection tranfection reagents and Supernuclease.
|T cell isolation and activation||• T cell activation antibodies|
|T cell genetically engineering||• CAR-T cell therapy targets for biopanning|
|• Sinofection tranfection reagents for lentiviral vectors transfection|
|• Supernuclease for removing DNA impurities in the process of lentiviral vector amplification.|
|CAR-T cell expansion||• High-quality cytokines for CAR-T cell culturing|
|CAR-T cell quality control and infusion into the body||• CAR-T cell therapy targets for detecting CAR+%|
|• T cell related FACS antibodies|
|• Cytokine ELISA kits|
|• Annexin V/7-AAD apoptosis detection kits for cytotoxicity assay|
Sino Biological Inc. have successfully developed over 6000 proteins, covering most of the investigational CAR-T cell therapy targets. We have developed biotinylated proteins and fluorescent labeled proteins to simplify your research procedures. The proteins with high purity and binding activity, have been validated in high-class citations. Therefore, CAR-T cell therapy target proteins in Sino Biological Inc. are the first choice for your scientific research. To view more about the CAR-T cell therapy targets.
|Target||Purity (by HPLC)||Endotoxin (EU/mg)||Cat. No.|
|Human CD3 (humanized OKT3)||>95%||<0.5||10977-H001|